Cite this answer
Ganirelix: quick citable summary
Ganirelix is listed by PeptaHub as a other peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Ganirelix: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/ganirelix. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/ganirelix.
What is Ganirelix?
Ganirelix (Antagon/Orgalutran) is an FDA-approved synthetic decapeptide GnRH antagonist for IVF. It rapidly suppresses LH without a flare effect, resulting in shorter stimulation protocols, lower FSH requirements, and reduced OHSS risk compared to GnRH agonist protocols.
Overview
Ganirelix is a synthetic decapeptide GnRH antagonist used in assisted reproductive technology to prevent premature LH surges and unintended ovulation during controlled ovarian hyperstimulation for IVF. Sold under the brand names Antagon (US) and Orgalutran (Europe), it offers rapid onset pituitary suppression without the flare effect associated with GnRH agonists, resulting in shorter stimulation protocols and better patient tolerability.
Mechanism of action
Ganirelix competitively binds to pituitary GnRH receptors with significantly higher binding affinity (Kd = 0.4 nM) than endogenous GnRH (Kd = 3.6 nM), rapidly suppressing LH and FSH secretion within hours. Multiple D-amino acid substitutions at positions 1, 2, 3, 6, 8, and 10 of the native GnRH decapeptide provide metabolic stability and prolonged receptor occupancy. Unlike GnRH agonists, ganirelix does not trigger receptor downregulation or an initial gonadotropin flare; suppression is immediate and fully reversible upon discontinuation. Steady-state plasma concentrations are achieved after 3 days of daily dosing, maintaining consistent LH suppression throughout the stimulation window.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| IVF — prevention of premature LH surge | subcutaneous | 0.25–0.25 mg | once daily | Initiate on stimulation day 5 or 6 (or when lead follicle reaches 14 mm). Continue until hCG trigger day. Administer at same time each day. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Ganirelix research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
Phase III trials established ganirelix 0.25 mg daily as the minimal effective dose preventing premature LH surges while optimizing ongoing pregnancy rates. Comparative studies versus leuprolide long protocols demonstrate equivalent clinical pregnancy rates with significantly fewer injection days and lower total FSH dosage. A large European multicenter trial (n=730) confirmed non-inferiority to buserelin long protocol. Post-marketing data indicate lower OHSS incidence versus GnRH agonist protocols, particularly in high-responder patients. Ganirelix is also being studied for endometriosis management.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Ganirelix for synergistic effects.
Legal status
FDA-approved (NDA 021057) for inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Prescription-only; administered under reproductive endocrinologist supervision. EMA-approved as Orgalutran.
Sourcing & access
Prescription required
Ganirelix is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Ganirelix is a synthetic decapeptide GnRH antagonist used in IVF to prevent premature luteinizing hormone surges and unintended ovulation during controlled ovarian stimulation. It is FDA-approved and sold as Antagon in the United States and Orgalutran in Europe. Multiple D-amino acid substitutions confer higher binding affinity than native GnRH and enable rapid, reversible pituitary suppression without an initial flare.
Both are GnRH antagonists used for the same purpose in IVF. Ganirelix has a slightly longer half-life (13 hours vs 5 hours for Cetrorelix at 0.25 mg) and higher binding affinity. Clinical outcomes are generally equivalent between the two agents.
Ganirelix 0.25 mg is initiated on stimulation day 5 or 6, or when the lead follicle reaches 14 mm. It is administered at the same time each day and continued until the hCG trigger day.
Common side effects include injection site reactions such as bruising, redness, and swelling, along with abdominal pain, headache, nausea, and vaginal bleeding. Ovarian hyperstimulation syndrome remains a class risk in controlled ovarian stimulation, though post-marketing data indicate lower OHSS incidence with ganirelix antagonist protocols compared to traditional GnRH agonist long protocols, particularly in high-responder patients.
Research references
- Large prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulationPubMed
- Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulationPubMed
- Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelixPubMed
- Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trialPubMed
- Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled studyPubMed